Ismail H A, Pollak M, Behlouli H, Tanguay S, Bégin L R, Aprikian A G
Department of Surgery, McGill University, and the Montreal General Hospital Research Institute, Montreal, Quebec, Canada.
BJU Int. 2003 Nov;92(7):699-702. doi: 10.1046/j.1464-410x.2003.04084.x.
To examine the relationship of serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3) with histological cancer characteristics in men undergoing transrectal ultrasonography (TRUS)-guided biopsy.
Patients (652), with either an elevated serum prostate-specific antigen level or an abnormal digital rectal examination, were initially evaluated by TRUS and sextant prostatic needle biopsy. Blood was drawn before biopsy, serum extracted and stored frozen until IGF-1 and IGFBP-3 were measured. In all, 241 patients had prostate cancer (37%) and were included in this study. The number of positive biopsies, the volume of tumour in each positive biopsy and the Gleason score were recorded.
Of the 241 patients, 37 had five or six positive biopsies (from six), 128 had two to four and 76 had one. Serum IGF-1 did not correlate with the number of positive biopsies, with means of 176.7, 178.3 and 164.4 ng/mL, respectively (P = 0.3), while the mean IGFBP-3 was 2695, 2795 and 2572 ng/mL, respectively (P = 0.09). The additive percentiles of tumour volume in positive biopsies were assessed for each patient but serum IGF-1 and IGFBP-3 did not correlate (P = 0.7 and 0.9, respectively). In all, 92 patients had a Gleason score of < 7, 80 a score of 7 and 69 a score of > 7; the mean (sd) IGF-1 levels for the three groups were 181 (39), 174.6 (35) and 176 (26) ng/mL, and the mean IGFBP-3 2798 (240), 2735 (284) and 2647 (221) ng/mL, respectively, none of the differences being statistically significant.
Serum IGF-1 and IGFBP-3 do not correlate with quantity of cancer or Gleason score in biopsy samples from patients with prostate cancer.
研究接受经直肠超声（TRUS）引导下活检的男性患者血清胰岛素样生长因子（IGF）-1和IGF结合蛋白-3（IGFBP-3）与前列腺癌组织学特征之间的关系。
652例血清前列腺特异性抗原水平升高或直肠指检异常的患者，首先接受TRUS和前列腺六分区穿刺活检评估。在活检前采集血液，提取血清并冷冻保存，直至检测IGF-1和IGFBP-3。共有241例患者患有前列腺癌（37%）并纳入本研究。记录阳性活检的数量、每次阳性活检中的肿瘤体积以及Gleason评分。
241例患者中，37例有5或6个阳性活检（共6个），128例有2至4个，76例有1个。血清IGF-1与阳性活检数量无关，其平均值分别为176.7、178.3和164.4 ng/mL（P = 0.3），而IGFBP-3的平均值分别为2695、2795和2572 ng/mL（P = 0.09）。对每位患者阳性活检中肿瘤体积的累加百分位数进行评估，但血清IGF-1和IGFBP-3无相关性（P分别为0.7和0.9）。共有92例患者Gleason评分为<7，80例评分为7，69例评分为>7；三组的平均（标准差）IGF-1水平分别为181（39）、174.6（35）和176（26）ng/mL，平均IGFBP-3分别为2798（240）、2735（284）和2647（221）ng/mL，差异均无统计学意义。
前列腺癌患者活检样本中血清IGF-1和IGFBP-3与癌灶数量或Gleason评分无关。
